The antiserum was produced against synthesized peptide derived from human NFAT4 around the phosphorylation site of Ser165. AA range:131-180

Phospho-NFATc3 (S165) Polyclonal Antibody detects endogenous levels of NFATc3 protein only when phosphorylated at S165.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SPsPA

NFATC3

Nuclear factor of activated T-cells cytoplasmic 3

NFATC3 ;
NFAT4 ;
Nuclear factor of activated T-cells ;
cytoplasmic 3 ;
NF-ATc3 ;
NFATc3 ;
NFATx ;
T-cell transcription factor NFAT4 ;
NF-AT4

The product of this gene is a member of the nuclear factors of activated T cells DNA-binding transcription complex. This complex consists of at least two components: a preexisting cytosolic component that translocates to the nucleus upon T cell receptor (TCR) stimulation and an inducible nuclear component. Other members of this family participate to form this complex also. The product of this gene plays a role in the regulation of gene expression in T cells and immature thymocytes. Several transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq , Nov 2010] ,

Domain:Rel Similarity Domain (RSD) allows DNA-binding and cooperative interactions with AP1 factors. ,Function:Plays a role in the inducible expression of cytokine genes in T-cells , especially in the induction of the IL-2. ,PTM:Phosphorylated by NFATC-kinase; dephosphorylated by calcineurin. ,similarity:Contains 1 RHD (Rel-like) domain. ,subcellular location:Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFATC is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals. The subcellular localization of NFATC plays a key role in the regulation of gene transcription. ,subunit:Member of the multicomponent NFATC transcription complex that consists of at least two components , a pre-existing cytoplasmic component NFATC2 and an inducible nuclear component NFATC1. Other members such as NFATC4 , NFATC3 or members of the activating protein-1 family , MAF , GATA4 and Cbp/p300 can also bind the complex. NFATC proteins bind to DNA as monomers. ,tissue specificity:Isoform 1 is predominantly expressed in thymus and is also found in peripheral blood leukocytes and kidney. Isoform 2 is predominantly expressed in skeletal muscle and is also found in thymus , kidney , testis , spleen , prostate , ovary , small intestine , heart , placenta and pancreas. Isoform 3 is expressed in thymus and kidney. Isoform 4 is expressed in thymus and skeletal muscle. ,

Cytoplasm . Nucleus . Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFATC is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals. The subcellular localization of NFATC plays a key role in the regulation of gene transcription.

>>MAPK signaling pathway ;
>>cGMP-PKG signaling pathway ;
>>Cellular senescence ;
>>Wnt signaling pathway ;
>>Axon guidance ;
>>C-type lectin receptor signaling pathway ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>Oxytocin signaling pathway ;
>>Yersinia infection ;
>>Hepatitis B ;
>>Human cytomegalovirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Human immunodeficiency virus 1 infection ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Lipid and atherosclerosis